Sale abandoned
Imperial College London spin-off Molecular Vision has called off discussions that were to have led to its sale to Swiss technology company Acrongenomics. Molecular Vision cites an inability to complete discussions to the terms and timetable agreed.
The sale had been announced in November 2007, and Acrongenomics still owns a 10.9 per cent stake in Molecular Vision. Work continues on the joint development agreement between the two companies that commenced in March 2006, says Molecular Vision.
Molecular Vision specialises in miniaturised point-of-care medical diagnositic devices that integrate microfluidic chips with organic-semiconductor technology and photodetectors to provide portable laboratory quality diagnostic tests in an easy-to-use, low-cost, disposable kit. The devices have the potential to test for multiple diagnostic markers simultaneously.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
